I like this for a more in depth explanation of the results....

I like this for a more in depth explanation of the results.
movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.29633
" This finding, together with the observation that clinical progression, correlates with imaging progression, suggests that the present lmaging biomarker anticipates anticipates clinical progression, and therefore qualifies as at least a medium grade surrogate marker of disease progression"
That ATH want to add the atrophy measurement as a primary trial endpoint, suggests they have already seen it in the open label study. If atrophy does anticipate clinical progression, you may be right Scott. exciting times ahead for holders and patients.